Australia markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.44+1.66 (+6.98%)
At close: 04:00PM EDT
26.50 +1.06 (+4.17%)
After hours: 07:09PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close23.78
Open23.94
Bid22.11 x 2200
Ask26.50 x 1000
Day's range23.94 - 25.59
52-week range15.83 - 25.68
Volume894,267
Avg. volume883,591
Market cap2.703B
Beta (5Y monthly)0.54
PE ratio (TTM)26.23
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

    Phase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel aloneMENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of

  • GlobeNewswire

    Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

    Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Figure 1 Figure 1 MENLO PARK, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that,

  • GlobeNewswire

    Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update

    MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2022. Financial Results Revenue of $93.7 million, compared to $79.4 million in first quarter 2021Reiterated 2022 revenue guidance